Pipeline

Related Links

Muscle Biology Cell Cycle Control Press Releases

Cardiovascular

ProductPreclinicalPhase IPhase IIPhase IIIStatus
   
 
Stable Heart Failure:
    
 
Safety and Tolerability (iv)
   
Phase II initiated in Q2 07 (3)
Cardiac Catheterization (iv)
   
Phase II to be initiated in 1H 08 (3)
Ischemic Cardiomyopathy (iv/oral)
   
Phase II to be initiated in 1H 08 (3)
Healthy Volunteers:
    
 
Drug/Drug Interaction (oral)
   
Phase I initiated in Q2 07 (3)
Single-Dose to Multi-Dose (oral)
   
Phase I completed Q4 07; awaiting data (3)
Oral Modified Release (oral)
   
Phase I initiated Q4 07 (3)

Oncology

ProductPreclinicalPhase IPhase IIPhase IIIStatus
   
 
Monotherapy:
    
 
Leukemia
   
Phase I initiated in 2004 (2)
Pediatric Solid Tumor
   
Phase I initiated in 2006 (2)
Breast Cancer
   
Phase I/II initiated 2007(3)**
Phase II POC completed in 2007*
Combination Therapy:
    
 
ispinesib&capecitabine
Multiple Tumor Types
   
Phase Ib completed in 2007; awaiting data (1)
      
   
 
Hodgkin/Non-Hodgkin Lymphoma
   
Phase I/II initiated in 2006 (3)
      
   
 
Advanced Solid Tumors
   
Phase I intiated in 2007 (1)

Current status as of 1/08

(1) Conducted by GSK
(2) Conducted by NCI
(3) Conducted by Cytokinetics

* Ispinesib studied as a second- or third-line treatment
** Ispinesib studied as a first-line treatment

Cytokinetics Program Status Program Status
Cytokinetics Ongoing Clinical Trial Ongoing Clinical Trial
Cytokinetics Program Status Planned Activity